Morgan Stanley downgraded DiaSorin (DSRLF) to Equal Weight from Overweight with a price target of EUR 63, down from EUR 99. The firm says macro headwinds continue to present earnings risk for medical technology services in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSRLF: